Research Funding

Grant Title Grantor Amount Award Date
Molly M. Fuentes, MD
The Experience of Disability in American Indian and Alaska Native Children, sub-award of the Rehabilitation Medicine Scientist Training Program (K12 program funded by the National Center for Medical and Rehabilitation Research) July 1, 2016 - June 30, 2019
Susan D. Apkon, MD
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY (H6D-MC-LVJJ) Eli Lilly and Company 2014 - 2016
Susan D. Apkon, MD
AN OPEN-LABEL, MULTI-CENTER, 48-WEEK STUDY WITH A CONCURRENT UNTREATED CONTROL ARM TO EVALUATE THE EFFICACY AND SAFETY OF ETEPLIRSEN IN DUCHENNE MUSCULAR DYSTROPHY Serepta Therapeutics 2014 - 2016
Susan D. Apkon, MD
AN OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF ETEPLIRSEN IN PATIENTS WITH ADVANCED STATE DUCHENNE MUSCULAR DYSTROPHY Serepta Therapeutics 2014 - 2016
Susan D. Apkon, MD
A PHASE 3 EFFICACY AND SAFETY STUDY OF ATALUREN (PTC 124) IN PATIENTS WITH NONSESNE MUTATION DYSTROPHINOPATHY PTC Therapeutics $ 2013 - 2016
Susan D. Apkon, MD
A PHASE 1, MULTI-CENTER, CONTROLLED, PROSEPCTIVE CORRELATIVE STUDY OF ELECTRICAL IMPEDENCE MYOGRAPHY IN MALES WITH DUCHENNE MUSCULAR DYSTROPHY AND IN HEALTHY MALES Holloran 2012 - 2012
Susan D. Apkon, MD
BOTOX TREATMENT IN PEDIATRIC UPPER LIMB SPASTICITY: DOUBLE-BLIND STUDY Allergan Pharmaceuticals 2012 - 2016
Susan D. Apkon, MD
BOTOX TREATMENT IN PEDIATRIC LOWER LIMB SPASTICITY: DOUBLE BLIND STUDY Allergan Pharmaceuricals 2012 - 2016
Susan D. Apkon, MD
DUCHENNE LONG-TERM IDEBENONE STUDY (DELOS): A PHASE III DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF IDEBENONE IN 10-18 YEAR OLD PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY Santhera Pharmaceuticals $ 2012 - 2014
Susan D. Apkon, MD
IMPACT OF WALKING ACTIVITY ON BONE HEALTH IN CHILDRENS WITH CEREBRAL PALSY Academic Enrichment Fund, Seattle Children's Hospital $40,000 2011 - 2016
Ross M. Hays, MD
Improving Family Outcomes With a Communication Intervention in the ICU NIH/NINR $506,867.00 Sept. 29, 2009
Susan Apkon, MD
A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy PTC Therapeutics $225,000.00 Jan. 1, 2008
Susan Apkon, MD
Use of Alendronate in Boys with Duchenne Muscular Dystrophy The Children’s Hospital Research Institute & Merck $30,000.00 Jan. 1, 2003
Susan Apkon, MD
Surveillance and Epidemiologic Research of Duchene and Becker Muscular Dystrophy and Other Single Gene Disorders Centers for Disease Control and Prevention $220,000.00 Dec. 1, 2002